2sev­en­ty: Nick Leschly brings a trio of top ex­ecs with him on top-speed flight from the blue­bird nest

Af­ter serv­ing more than a decade as blue­bird bio’s chief blue­bird, Nick Leschly is switch­ing it up.

At some point this year, Leschly will of­fi­cial­ly be­come the CEO of 2sev­en­ty — the new com­pa­ny that will house blue­bird’s on­col­o­gy busi­ness while An­drew Oben­shain, the cur­rent pres­i­dent for se­vere ge­net­ic dis­eases, will take over as CEO to over­see the rare dis­ease pipeline re­main­ing at blue­bird.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER